Literature DB >> 9610339

Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts.

G J Fulton1, M G Davies, L Barber, J L Gray, E Svendsen, P O Hagen.   

Abstract

OBJECTIVES: The universal response of vein grafts after insertion into the arterial circulation is the development of intimal hyperplasia; smooth muscle cell proliferation and connective tissue deposition, which may be modulated in part by dysfunctional endothelial nitric oxide (NO) metabolism. This study examines the effects of single dose, local application by pluronic gel of a NO donor, S-nitroso-N-acetylpenicillamine (SNAP) and an NO synthase inhibitor nitro-L-arginine methyl ester (L-NAME) on the formation of intimal hyperplasia. MATERIALS: Forty New Zealand white rabbits underwent jugular vein interposition grafting of the common carotid artery.
DESIGN: Ten animals were controls, 10 animals had the outer surface of the vein graft coated with 30% pluronic gel (2.5 ml), and 10 each were immersed for 15 min prior to insertion in Ringer lactate containing 10(-3) M of SNAP or L-NAME and then had their vein grafts coated with 2.5 ml of gel containing either SNAP (10(-3) M) or L-NAME (10(-3) M), which allows for sustained delivery for up to 6 h. On the 28th post operative day, the animals were sacrificed and vein grafts were harvested for morphology by electron microscopy (SEM and TEM) and dimensional analysis by videomorphometry.
RESULTS: All vein grafts developed intimal hyperplasia. On SEM the vein grafts had a confluent layer of endothelial cells with multiple layers of smooth muscle cells representing intimal hyperplasia in TEM. There were no demonstrable morphological differences between the four groups. Local treatment with SNAP produced a significant 36% decrease in mean intimal thickness (72 +/- 4 microns vs. 45 +/- 4 microns; mean +/- S.E.M.; p < 0.01) without a change in medial thickness compared to gel-only treated groups (58 +/- 6 microns vs. 61 +/- 7 microns; p = ns). Inhibition of NO synthase by L-NAME had no effect on the development of intimal hyperplasia (72 +/- 4 microns vs. 79 +/- 10 microns; p = ns); medial thickness was also unchanged.
CONCLUSION: These data confirm the protective effect of NO in vascular injury and suggest that NO synthase activity is either absent or reduced to such a level that further inhibition in this short time course is not relevant to the pathophysiology of vein graft intimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610339     DOI: 10.1016/s1078-5884(98)80030-0

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  9 in total

1.  Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia.

Authors:  Ashley K Vavra; George E Havelka; Janet Martinez; Vanessa R Lee; Bo Fu; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2011-04-30       Impact factor: 4.427

2.  Poly(diol-co-citrate)s as novel elastomeric perivascular wraps for the reduction of neointimal hyperplasia.

Authors:  M Concepcion Serrano; Ashley K Vavra; Michele Jen; Melissa E Hogg; Jozef Murar; Janet Martinez; Larry K Keefer; Guillermo A Ameer; Melina R Kibbe
Journal:  Macromol Biosci       Date:  2011-02-21       Impact factor: 4.979

3.  Nitric oxide delivery via a permeable balloon catheter inhibits neointimal growth after arterial injury.

Authors:  George E Havelka; Edward S Moreira; Monica P Rodriguez; Nick D Tsihlis; Zheng Wang; Janet Martínez; Joseph A Hrabie; Larry K Kiefer; Melina R Kibbe
Journal:  J Surg Res       Date:  2012-11-10       Impact factor: 2.192

4.  Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistula.

Authors:  Maheshika Somarathna; Patrick Tj Hwang; Reid C Millican; Grant C Alexander; Tatyana Isayeva-Waldrop; Jennifer A Sherwood; Brigitta C Brott; Isabelle Falzon; Hannah Northrup; Yan-Ting Shiu; Chris J Stubben; John Totenhagen; Ho-Wook Jun; Timmy Lee
Journal:  Biomaterials       Date:  2021-11-18       Impact factor: 15.304

5.  Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury.

Authors:  Edward S M Bahnson; Hussein A Kassam; Tyson J Moyer; Wulin Jiang; Courtney E Morgan; Janet M Vercammen; Qun Jiang; Megan E Flynn; Samuel I Stupp; Melina R Kibbe
Journal:  Antioxid Redox Signal       Date:  2016-01-21       Impact factor: 8.401

6.  Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia.

Authors:  Muneera R Kapadia; Lesley W Chow; Nick D Tsihlis; Sadaf S Ahanchi; Jason W Eng; Jozef Murar; Janet Martinez; Daniel A Popowich; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; James F Hulvat; Samuel I Stupp; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2008-01       Impact factor: 4.268

7.  Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome.

Authors:  Sadaf S Ahanchi; Vinit N Varu; Nick D Tsihlis; Janet Martinez; Charles G Pearce; Muneera R Kapadia; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Joseph A Hrabie; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

8.  Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia.

Authors:  Charles G Pearce; Samer F Najjar; Muneera R Kapadia; Jozef Murar; Jason Eng; Brian Lyle; Oliver O Aalami; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe
Journal:  Free Radic Biol Med       Date:  2007-09-25       Impact factor: 7.376

9.  Experimental implantation of an arterial substitute made of silicone reinforced with polyester fabric in rabbits.

Authors:  Laila Massad Ribas; Inez Ohashi Torres; Fernanda Appolonio; Karina Paula Domingos Rosa; Fabio Rodrigues Ferreira do Espírito-Santo; Nelson De Luccia
Journal:  Clinics (Sao Paulo)       Date:  2017-12       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.